141 related articles for article (PubMed ID: 35073638)
1. Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.
Duro T; Li S; Jose D; Khawar T
J Clin Rheumatol; 2021 Dec; 27(8S):S656. PubMed ID: 35073638
[No Abstract] [Full Text] [Related]
2. Palmoplantar pustulosis secondary to anti-tumor necrosis factor therapy in a patient with ankylosing spondylitis.
Bae JM; Eun SH; Kim KJ
Korean J Intern Med; 2020 Jan; 35(1):254-255. PubMed ID: 31623028
[No Abstract] [Full Text] [Related]
3. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
Dong Y; Li P; Xu T; Bi L
Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
[TBL] [Abstract][Full Text] [Related]
4. Muscular sarcoidosis under anti-TNF treatment in ankylosing spondylitis.
Wendling D; Nueffer JP
Joint Bone Spine; 2018 Dec; 85(6):769. PubMed ID: 29787812
[No Abstract] [Full Text] [Related]
5. Scrotal pain of a patient with ankylosing spondylitis successfully treated with TNF-alpha inhibitor: a case report.
Suzuki H; Tsujimoto T; Ota M; Hasegawa Y; Oha F; Shimamura Y; Tanaka M; Hashimoto T; Iwasaki N; Kanayama M
J Orthop Sci; 2024 Jan; 29(1):402-404. PubMed ID: 35690543
[No Abstract] [Full Text] [Related]
6. Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.
Provenzano G; Arcuri C; Miceli MC
Clin Rheumatol; 2021 Jan; 40(1):425-427. PubMed ID: 32776313
[No Abstract] [Full Text] [Related]
7. Etanercept for Ankylosing Spondylitis With Coexisting Demyelinating Myelitis.
Ye C; Geng Z; Li S; Yu F
Am J Ther; 2019; 26(5):e629-e631. PubMed ID: 30199382
[No Abstract] [Full Text] [Related]
8. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
9. Comment on "Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
Maatallah K; Ben Nessib D; Hamdi W
Clin Rheumatol; 2021 May; 40(5):2109-2110. PubMed ID: 33754223
[No Abstract] [Full Text] [Related]
10. Rebuttal letter on "Comment on Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature".
Rocha FAC; Deodhar A
Clin Rheumatol; 2021 May; 40(5):2107-2108. PubMed ID: 33754222
[No Abstract] [Full Text] [Related]
11. Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitors.
Ma KS; Kao PE; Chen KH; Liu CH
Int J Rheum Dis; 2023 Jul; 26(7):1412-1413. PubMed ID: 36941023
[No Abstract] [Full Text] [Related]
12. Biosimilars and retention rates in patients with ankylosing spondylitis.
Pelechas E; Kaltsonoudis E; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2021; 39(2):440. PubMed ID: 33124580
[No Abstract] [Full Text] [Related]
13. Relapsing Polychondritis in a Patient with Ankylosing Spondylitis under Two Different Tumor Necrosis Factor Alpha Inhibitors Treatment.
İçaçan OC; Yalçın Mutlu M; Yıldırım F; Bes C
Clin Ter; 2022 Apr; 173(2):97-98. PubMed ID: 35385029
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha therapy for ankylosing spondylitis.
Son JH; Cha SW
Clin Orthop Surg; 2010 Mar; 2(1):28-33. PubMed ID: 20190998
[TBL] [Abstract][Full Text] [Related]
15. Demyelination during anti-TNFα therapy for ankylosing spondylitis.
Mercieca C; Vella N; Borg AA
Mod Rheumatol; 2012 Apr; 22(2):303-7. PubMed ID: 21748364
[TBL] [Abstract][Full Text] [Related]
16. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.
Psarelis S; Hajineocli APD; Hadjicosta E; Elliott HSA; Johnson P
Clin Rheumatol; 2017 May; 36(5):1197-1199. PubMed ID: 28233109
[TBL] [Abstract][Full Text] [Related]
17. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
18. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
19. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
[TBL] [Abstract][Full Text] [Related]
20. Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.
Lee SH; Kim YG; Lee SG; Lee SH; Kim YJ; Jeon JY; Jo JY; Yoo HJ; Lee J; Kim TH
Int J Rheum Dis; 2022 May; 25(5):523-531. PubMed ID: 35187866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
